Synthèses générées par IA. Vérifiez chaque affirmation auprès des sources citées avant d’agir. Lire notre méthodologie

← Retour à tous les rapports

Histiocytose des cellules de Langerhans

Des efforts de recherche récents visant à guérir l'histiocytose des cellules de Langerhans.

Mis à jour le

Histiocytose des cellules de Langerhans

Overview

Langerhans Cell Histiocytosis (LCH) est une néoplasie myéloïde inflammatoire rare dans laquelle des cellules immunitaires anormales s’accumulent dans les tissus et peuvent former des lésions destructrices dans l’os, la peau, les poumons, l’hypophyse, le foie, la rate, la moelle osseuse et d’autres organes. Elle survient le plus souvent chez les jeunes enfants mais peut apparaître à tout âge. Le pronostic est généralement très favorable pour une maladie à siège unique, tandis que la maladie multisystémique impliquant le foie, la rate ou la moelle osseuse peut être potentiellement mortelle et peut laisser des survivants avec des complications permanentes telles que diabète insipide, déficits hormonaux, atteinte pulmonaire ou des problèmes neurologiques. NCI PDQ treatment summary (cancer.gov)

Current care is tailored to disease extent. A single bone or skin lesion may be observed after biopsy, treated locally, or treated with limited systemic therapy; multisystem childhood LCH is commonly treated with vinblastine plus prednisone, while adult multisystem disease more often uses cytarabine- or cladribine-based regimens. Smoking cessation is central treatment for isolated pulmonary LCH. Targeted inhibitors of the MAPK signaling pathway are increasingly used for relapsed, refractory, or selected high-risk disease, but they are not yet established as universally curative first-line therapy. NCI PDQ treatment summary International adult consensus recommendations (cancer.gov)

Scope of Recent Research (2020–present)

Research activity since 2020 has been substantial, driven by the recognition that most LCH lesions have activating mutations in the MAPK pathway, especially BRAF^V600E, and by the unmet need to prevent relapse and irreversible late effects. The leading questions are whether MAPK inhibitors can be safely moved earlier in care, how long they must be continued, which patients need intensive chemotherapy, and—most importantly—how to eliminate the mutated blood-forming stem or progenitor cells believed to survive current targeted therapy. Thus, the field has achieved major advances in disease control, but a reliably curative molecular therapy remains unproven. Histiocyte Society research blueprint (haematologica.org)

Major Breakthroughs and Emerging Therapies

The central therapeutic breakthrough is precision inhibition of the MAPK pathway, a cell-growth signaling route abnormally activated in most LCH. BRAF inhibitors such as vemurafenib and dabrafenib directly target BRAF^V600E, while MEK inhibitors such as trametinib, cobimetinib, and luvometinib act further downstream and can potentially work across several MAPK mutations. In pediatric BRAF-mutant LCH, early-phase studies of dabrafenib alone or with trametinib showed investigator-assessed objective responses in 76,9 % and 58,3 % of participants, respectively, with adverse effects consistent with these drug classes. Dabrafenib and trametinib pediatric study (pubmed.ncbi.nlm.nih.gov)

A particularly important recent result came from a genotype-agnostic phase 2 study of the MEK inhibitor luvometinib in children with recurrent or refractory LCH. Published on July 29, 2026, the trial enrolled 46 children; among 42 evaluable participants, independent review found a 90,5 % objective response rate, and MAPK-mutation levels in cell-free DNA became undetectable in 15 sur 19 evaluable patients. These results show that broad MEK inhibition can achieve rapid, high response rates even when treatment is not limited to one named mutation. Luvometinib phase 2 trial (nature.com)

Conventional chemotherapy is also being refined rather than replaced. A multicenter cohort of 58 heavily pretreated pediatric and adult patients found that single-agent clofarabine produced a 92,6 % systemic objective response rate, supporting it as a less intensive salvage option than high-dose cladribine-plus-cytarabine combinations for some patients with aggressive relapsed disease. This is not a targeted cure, but it may provide durable control while avoiding some of the severe toxicity associated with more intensive salvage chemotherapy. Clofarabine monotherapy cohort (pmc.ncbi.nlm.nih.gov)

No clinical gene-editing, gene-replacement, RNA, or cell therapy has yet demonstrated a cure for LCH. The most cure-oriented experimental idea is to eradicate or permanently correct the MAPK-mutated hematopoietic stem/progenitor clone rather than merely suppress its descendants in lesions. Preclinical mouse, xenograft, induced-pluripotent-stem-cell, and brain-microglia models are being used to test that hypothesis and to identify combinations—such as targeted therapy plus chemotherapy or inflammation-directed treatment—that could clear the initiating clone and prevent relapse or neurodegeneration. Histiocyte Society research blueprint (haematologica.org)

Clinical Trials and Experimental Approaches

The large international LCH-IV protocol, sponsored in North America by the North American Consortium for Histiocytosis (NACHO) with the Histiocyte Society as collaborator, remains a major pediatric platform study. It tests risk-adapted approaches including longer continuation therapy, salvage chemotherapy for poor responders, reduced-intensity allogeneic stem-cell transplantation for selected severe refractory cases, and systematic long-term follow-up for late effects. Its principal goal is to reduce reactivation without exposing lower-risk children to unnecessary treatment. LCH-IV trial record Histiocyte Society research blueprint (clinicaltrials.gov)

Other notable phase 2 efforts include NACHO’s cobimetinib study for refractory LCH and related histiocytic disorders, which evaluates one-year response and adverse effects; a pediatric phase 2 trial of trametinib for newly or recently diagnosed LCH that also incorporates tumor, matched-normal, and liquid-biopsy sequencing; and the completed luvometinib study in relapsed or refractory pediatric LCH. The latter is the strongest recent prospective efficacy signal, but longer follow-up after drug discontinuation is needed before interpreting high response rates as durable cures. Cobimetinib phase 2 trial Trametinib pediatric phase 2 trial Luvometinib phase 2 trial (clinicaltrials.gov)

Methodologies and Scientific Approaches

Researchers increasingly combine lesion sequencing with blood-based testing. Digital PCR and next-generation sequencing can measure BRAF^V600E and other MAPK mutations in circulating cell-free DNA, providing a minimally invasive way to estimate molecular disease burden. In children, detectable cell-free BRAF^V600E at diagnosis has been associated with poorer progression-free survival and higher risk of progression or reactivation, making it a promising tool for risk stratification and response monitoring. Cell-free BRAF prognostic study Histiocyte Society research blueprint (pubmed.ncbi.nlm.nih.gov)

Mechanistic research uses engineered mouse models, patient-derived cells, xenografts, single-cell sequencing, and induced-pluripotent-stem-cell models. These approaches test when and where a MAPK mutation arises, whether the mutation persists in blood-forming stem cells during clinical remission, and how mutated cells contribute to late neurologic injury. A key goal is to develop biomarkers that distinguish patients likely to be cured with limited therapy from those who need early intensification or a clone-eradicating strategy. Histiocyte Society research blueprint (haematologica.org)

Leading Institutions and Funding

The Histiocyte Society provides the main international research framework for pediatric LCH, while NACHO coordinates North American clinical studies and biology programs. Major participating centers include St. Jude Children’s Research Hospital, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Children’s Hospital of Philadelphia, Cincinnati Children’s Hospital Medical Center, and other consortium sites. NACHO reports multiyear St. Baldrick’s Foundation consortium support, with additional support for individual trials from Cookies for Kids’ Cancer, the Histiocytosis Association, the Leukemia & Lymphoma Society, Cures Within Reach, Incyte, and Genentech. NACHO consortium members NACHO support programs (nacho-consortium.org)

Disease-specific philanthropic funding remains important in this rare condition. The Histiocytosis Association’s 2024 program offered grants of up to $50,000 each for research on causes, mechanisms, and improved treatment of histiocytic disorders. In 2026, the U.S. National Cancer Institute awarded Baylor College of Medicine $321,000 for a project examining inherited and acquired genetic variants in LCH pathogenesis, including large-scale pediatric genomic data. Histiocytosis Association research grants NCI award: LCH genetic variants (histio.org)

Strengths, Limitations, and Challenges

The field’s major strength is that LCH now has actionable biology: MAPK inhibitors can produce striking responses, often more rapidly and less destructively than repeated intensive chemotherapy. Molecular testing, liquid-biopsy monitoring, and multicenter protocols are making treatment more individualized. The high phase 2 response rate with luvometinib and the activity of clofarabine in heavily pretreated disease expand options for patients whose LCH returns or fails initial treatment. Luvometinib phase 2 trial Clofarabine monotherapy cohort (nature.com)

The central limitation is that clinical remission is not necessarily molecular eradication. BRAF-mutated cells can persist in blood and bone marrow during MAPK-inhibitor treatment, and many patients relapse after stopping therapy; prolonged inhibitor use also raises questions about toxicity, adherence, cost, access, and effects on development in children. The rarity and biological diversity of LCH make randomized trials difficult, and no consensus yet defines optimal drug combinations, duration, molecular endpoints, or management of neurodegenerative LCH. Histiocyte Society research blueprint International adult consensus recommendations (haematologica.org)

Outlook and Future Directions

As of August 8, 2026, LCH is closer to precision disease control than to a universal cure. The most meaningful milestones to watch are durable off-treatment remissions after MAPK inhibition, prospective validation of cell-free DNA as a treatment-guiding biomarker, evidence that combination strategies can eliminate mutated stem/progenitor cells, and long-term results from LCH-IV and newer targeted-therapy trials. A cure is plausible for more patients if research can move from shrinking lesions to proving eradication of the disease-initiating clone while preventing irreversible endocrine and neurologic injury. Histiocyte Society research blueprint Luvometinib phase 2 trial (haematologica.org)

Références

Votre maladie n'apparaît pas ? Demandez un rapport